Significance of HER2 in Microinvasive Breast Carcinoma
Open Access
- 25 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 156 (1) , 155-165
Abstract
Objectives: We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)–expressing and nonexpressing microinvasive breast carcinomas (MiBC) to explore the significance of HER2 in MiBC. Methods: Clinicopathologic and follow-up information of cases with final diagnosis of MiBC with known HER2 status between 2007 and 2019 were analyzed. Results: Nineteen (41.3%) HER2-positive (HER2+) and 27 (58.7%) HER2-negative (HER2−) MiBCs were identified. HER2 positivity was likely to be associated with high nuclear grade, presence of tumor-infiltrating lymphocytes, hormonal receptor negativity, and increased Ki-67 in both microinvasive and associated in situ carcinomas. Nodal metastases were found in 2 ER+/HER2− cases (5.3%). One HER2+ case was found to have isolated tumor cells in the axillary node. The majority of patients with HER2+ MiBCs (76.5%) did not receive HER2-targeted therapy. All patients with available follow-up were alive without recurrence or distant metastasis, with a median follow-up of 38 months. Conclusions: Similar to the larger size of invasive breast carcinomas, HER2 positivity is associated with high-grade morphologic features in MiBCs. However, HER2 overexpression in MiBCs does not appear to be associated with nodal metastasis or worse outcome in our study cohort. The role of HER2-targeted therapy in this clinical setting merits additional study.Keywords
This publication has 33 references indexed in Scilit:
- Microinvasive breast carcinoma: An analysis from ten Senonetwork Italia breast centresEuropean Journal of Surgical Oncology, 2019
- Microinvasive Carcinoma versus Ductal CarcinomaIn Situ: A Comparison of Clinicopathological Features and Clinical OutcomesJournal of Breast Cancer, 2018
- Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013The American Journal of Surgery, 2016
- Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case reportBMC Research Notes, 2014
- Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristicsHuman Pathology, 2013
- Microinvasive Breast Cancer: ER, PR, and HER-2/neu Status and Clinical Outcomes after Breast-Conserving Therapy or MastectomyAnnals of Surgical Oncology, 2012
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of TherapyThe Oncologist, 2003
- Breast Cancer in the 21st Century: Neu Opportunities and Neu ChallengesLaboratory Investigation, 2001
- Microinvasive Carcinoma (T1mic) of the BreastAmerican Journal of Surgical Pathology, 2000
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.Journal of Clinical Oncology, 1992